Advertisement
U.S. markets closed
Advertisement

Emmaus Life Sciences, Inc. (EMMA)

Other OTC - Other OTC Delayed Price. Currency in USD
Visitors trend2W10W9M
0.1200-0.0030 (-2.44%)
At close: 03:45PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.1230
Open0.1200
Bid0.0000 x 1800
Ask0.0000 x 1300
Day's Range0.1200 - 0.1200
52 Week Range0.0850 - 0.5900
Volume1,016
Avg. Volume30,336
Market Cap6.437M
Beta (5Y Monthly)1.80
PE Ratio (TTM)N/A
EPS (TTM)-0.0800
Earnings DateNov 14, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for EMMA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • EMMAUS LIFE SCIENCES INC NEW
    Daily – Vickers Top Insider Picks for 03/21/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • PR Newswire

    Emmaus Life Sciences Reports Q3 2023 Financial Results

    Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2023.

  • PR Newswire

    Emmaus Life Sciences Reports Management Changes

    Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported that on August 18, 2023 the Board of Directors, including Yutaka Niihara, M.D., Ph.D, determined that Dr. Niihara would no longer serve as Chief Executive Officer of Emmaus, or as Chairman of the Board, in order to allow Dr. Niihara to pursue business opportunities in Ube, Japan and in India previously initiated by Emmaus. Dr. Niihara was the p

  • PR Newswire

    Emmaus Life Sciences Reports Q2 2023 Financial Results

    Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2023.